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The cell of origin formostmesenchymal tumors is un-
clear. One cell type that contributes to this lineages
is the pericyte, a cell expressing Ng2/Cspg4. Using
lineage tracing, we demonstrated that bone and
soft tissue sarcomas driven by the deletion of the
Trp53 tumor suppressor, or desmoid tumors driven
by a mutation in Apc, can derive from cells express-
ingNg2/Cspg4. Deletion of the Trp53 tumor suppres-
sor gene in these cells resulted in the bone and soft
tissue sarcomas that closely resemble human sar-
comas, while stabilizing b-catenin in this same cell
type caused desmoid tumors. Comparing expres-
sion between Ng2/Cspg4-expressing pericytes lack-
ing Trp53 and sarcomas that arose from deletion of
Trp53 showed inhibition of b-catenin signaling in
the sarcomas. Activation of b-catenin inhibited the
formation and growth of sarcomas. Thus, pericytes
can be a cell of origin for mesenchymal tumors, and
b-catenin dysregulation plays an important role in
the neoplastic phenotype.
INTRODUCTION
Tumors are initiated by mutations in specific cell types. Since
progenitor cell populations can survive over longer periods of
time, they may be more likely to accumulate mutations that
cause neoplasia (Reya et al., 2001). Identifying the cell of origin
of a tumor type can be used to identify critical events responsible
for tumor formation, and driving oncogenesis in the cell of origin
can be used to develop animal models that more accurately
recapitulate human tumors (Visvader, 2011).This is an open access article undSarcomas are malignancies found in the connective tissues,
composed of cells with mesenchymal characteristics. There is
a broad range of sarcoma types, including those that derive
in bone, cartilage, fat, muscle, or vascular, tissues. Two of
the most common sarcoma types are osteosarcoma and undif-
ferentiated pleomorphic sarcomas, and yet much remains to be
established about the critical steps required for tumor forma-
tion in these subtypes. Desmoid tumors are locally invasive
mesenchymal tumors that do not metastasize. They are
composed of fibroblast-like cells with a proliferative advantage,
driven by somatic mutations activating b-catenin mediated
signaling. Mutations in Apc or in b-catenin itself are identified
in almost all cases of this tumor type (Alman et al., 1997a;
Cheon et al., 2002). The precise cell of origin for these tumors
is unknown. Since they have mesenchymal characteristics,
it is likely that they derive from a mesenchymal lineage
progenitor cell.
In addition to its role in desmoid tumors, b-catenin protein is
also implicated in sarcomas. However, its role in sarcomas has
been controversial. Some studies suggest that activated b-cate-
nin signaling is important to drive the neoplastic phenotype,
while others found an opposite effect (Cai et al., 2010, 2014;
Du et al., 2014; Matushansky et al., 2007; Wan et al., 2014).
In mesenchymal cell development, b-catenin is precisely regu-
lated at different stages for normal differentiation, raising the
possibility that either high or low b-catenin leads to pathology
(Chen et al., 2007; Hoffman and Benoit, 2013; Li et al., 2008;
Wan et al., 2013). Understanding the role of b-catenin-
mediated signaling in neoplasia also has therapeutic implica-
tions, as b-catenin-modulating therapies are being developed
for clinical use.
Pericytes are mesenchymal cells that surround endothelial
cells in capillaries, venules, and small arterioles (Dı´az-Flores
et al., 2009; Hirschi and D’Amore, 1996). These cells express
markers such as chondroitin sulfate proteoglycan 4 (CSPG4),Cell Reports 16, 917–927, July 26, 2016 ª 2016 The Author(s). 917
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Mesenchymal Tumors Can Derive
from Ng2/Cspg4-Expressing Cells
(A) X-gal staining in Ng2/Cspg4-CreER;
Rosa26RlacZ mice, showing blue staining (LacZ) in
the brain (left) and in perivascular tissues in the
skeletal muscle (right).
(B) Representative H&E, X-gal staining, and a
radiograph from a mouse osteosarcoma that
developed in a Trp53-deficient mouse, showing
tumor cells that stained blue, indicating that they
are derived from Ng2/Cspg4-expressing cells.
(C) Representative H&E and X-gal staining from a
mouse soft tissue sarcoma that developed in a
Trp53-deficient mouse showing histology consis-
tent with undifferentiated pleomorphic sarcoma.
Similar to the situation in osteosarcomas, tumor
cells stained blue.
(D) Representative X-gal staining from a mouse
desmoid tumor that developing in an Apc1638N
mouse showing blue staining in the tumor cells.
This shows that these benign mesenchymal tu-
mors also derived from Ng2/Cspg4-expressing
cells.also termed neuron-glial antigen 2 (NG2), and CD146, also
known as melanoma cell adhesion molecule (Bergers and
Song, 2005; Covas et al., 2008; Crisan et al., 2008, 2012). This
cell type is involved in the stability and contractility of blood ves-
sels but also can be a progenitor for several mesenchymal cell
types (Crisan et al., 2008, 2012; Dellavalle et al., 2007). Interest-
ingly, human sarcomas are known to express genes that are
characteristically expressed in pericytes (Benassi et al., 2009;
Schiano et al., 2012). Thus, pericytes could be a cell of origin
for some mesenchymal tumors.
Here, we addressed the role of Ng2/Cspg4-expressing cells
and b-catenin in the origin of mesenchymal tumors. Lineage-
tracing studies in murine sarcomas driven by the deletion of
the Trp53 tumor suppressor, or desmoid tumors driven by a mu-
tation in Apc, were used to investigate Ng2/Cspg4-expressing
cells as a cell of origin for mesenchymal tumors. We also
determined the ability of Trp53 deletion and/or stabilization of
b-catenin in Ng2/Cspg4-expressing cells to result in tumor
formation.
RESULTS
Mesenchymal Tumors Can Derive from Ng2/Cspg4-
Expressing Cells
To determine if mesenchymal tumors might derive from Ng2/
Cspg4-expressing cells, we undertook lineage-tracing studies
in genetically modified mice that are known to develop mesen-
chymal tumors. We used Trp53 deficient mice to study sar-
comas. These mice are a model for Li-Fraumeni syndrome and
develop malignancies, including lymphomas and sarcomas
(Jacks et al., 1994). To study the origin of a benign tumor, we
investigated desmoid tumors, which are benign locally invasive918 Cell Reports 16, 917–927, July 26, 2016mesenchymal lesions driven bymutations
activating b-catenin-mediated signaling.
The Apc1638N mouse (Smits et al.,1998) harbors a mutation in Apc that results in the development
of multiple desmoid tumors.
NG2/CSPG4 is a cell-surface proteoglycan expressed by
pericytes, neural progenitor cells, chondrocytes, and hair folli-
cles (Feng et al., 2010). To label Ng2/Cspg4-expressing cells,
we crossed Ng2/Cspg4-CreER mice (Zhu et al., 2011) with
Rosa26RlacZ mice (Soriano, 1999). The transgene was activated
by daily tamoxifen injections for 1 week after weaning (Madisen
et al., 2010). b-Galactosidase (X-gal) staining was performed to
identify the distribution of LacZ-positive cells, and this confirmed
that LacZ was expressed in pericytes, neural cells, chondro-
cytes, and hair follicles (Figures 1A and S1A). In contrast, osteo-
blasts did not show expression of LacZ, a finding consistent with
other studies using this animal (Feng et al., 2011), in which LacZ
staining was only observed in bone during mesenchymal repair
processes when the transgene was activated postnatally (Fig-
ure S1B). To verify which cells were expressing LacZ, we disso-
ciated cells and sorted LacZ-positive and negative populations
as in our previous publications (Amini-Nik et al., 2011, 2014).
There was an increase in RNA expression of Ng2/Cspg4 in the
LacZ-positive population (Figure S1C). We next sorted NG2/
CSPG4-positive and negative cells using a cell-surface antibody
and analyzed the populations for expression of LacZ, finding that
the NG2/CSP4-positive population expressed LacZ. We also
analyzed the LacZ-positive and negative populations for the
expression of CD146, a cell-surface marker expressed by peri-
cytes (Wei et al., 2015), and found that the LacZ-expressing
cells also expressed CD146 (Figure S1E). Taken together, these
data show that LacZ effectively labels Ng2/Cspg4-expressing
pericytes.
We next crossed Ng2/Cspg4-CreER;Rosa26RlacZ mice with
Trp53-deficient mice (Jacks et al., 1994) and injected them
Table 1. Tumor Distribution of Ng2/Cspg4-Cre-Mediated Trp53 Conditional Knockout Mice
Genotype
Number
of Mice Bone Sarcoma (OS)
Soft Tissue
Sarcoma (UPS) Lymphoma
Other
Malignancies
Average Latency of Sarcoma
Development (days ± SD)
Ng2/Cspg4-Cre; Trp53flox/flox 50 38 (76.0%) 8 (16.0%) 2 (4.0%) 0 299 ± 56
Male 19 10 (52.6%) 6 (31.6%) 0 0 337 ± 59
Female 31 28 (90.3%) 2 (9.7%) 2 (6.5%) 0 280 ± 44
Ng2/Cspg4-Cre; Trp53flox/ 16 13 (81.2%) 3 (18.8%) 0 0 297 ± 61
Male 4 2 (50.0%) 2 (50.0%) 0 0 212 ± 49
Female 12 11 (91.7%) 1 (8.3%) 0 0 318 ± 43
Ng2/Cspg4-CreER; Trp53flox/flox 30 20 (66.0%) 6 (20%) 0 0 361 ± 59
Male 10 6 2 0 0 324 ± 64
Female 20 14 4 0 0 380 ± 56
NG2-Cre; Trp53flox/+ 12 0 1 (8.3%) 0 0 407with tamoxifen. 12 sarcomas developed in the mice; 5 were
undifferentiated pleomorphic sarcomas, 6 were osteosar-
comas, and 1 was an angiosarcoma. X-gal staining confirmed
that the sarcomas derived from LacZ-expressing cells (Figures
1B and 1C). Given the expression pattern of LacZ in normal
tissues, this suggests that the tumors derived from pericytes.
The Apc1638N mouse (Smits et al., 1998) harbors a muta-
tion in Apc that results in b-catenin activation and the
development of multiple desmoid tumors. Ng2/Cspg4-CreER;
Rosa26RlacZ mice were crossed with Apc1638N mutant mice
and injected them with tamoxifen. X-gal staining showed
that the desmoid tumors that developed also express LacZ
(Figure 1D).
Interestingly, not all cells stained blue. Solid tumors contain a
subpopulation of non-tumoral cells, including normal stromal
cells (Mao et al., 2013), but in mesenchymal tumors, there are
no cytologic or cell-surface markers to distinguish stromal cells
from neoplastic cells, making differentiation between tumoral
and stromal cells problematic. We sorted LacZ-stained from
non-stained cells in these tumors. Between 28% and 49% of
cells in the tumors did not stain with LacZ. In desmoid tumors,
we found a higher level of b-catenin in the LacZ-positive cells
(Figure S2). Thus, there is a population of normal cells within
bulk mesenchymal tumors that arise from non-Ng2/Cspg4-
expressing cells.
Trp53 Deletion in Ng2/Cspg4-Expressing Cells Induces
Bone and Soft Tissue Sarcomas
To determine whether mutations in Ng2/Cspg4-expressing cells
could induce sarcomas, we crossed Ng2/Cspg4-Cre mice or
Ng2/Cspg4-CreER mice with Trp53flox/flox mice (Marino et al.,
2000) to generate Ng2/Cspg4-Cre-mediated Trp53 conditional
knockout mice. In the case of mice expressing the Ng2/
Cspg4-CreER allele, the conditional allele was activated by
tamoxifen administration the week following weaning. In Ng2/
Cspg4-CreER;Trp53flox/flox mice treated with tamoxifen, 66%
developed bone sarcomas and 20% developed soft tissue
sarcomas. In Ng2/Cspg4-Cre;Trp53flox/flox mice in which Cre is
constitutively expressed in Ng2/Cspg4+ cells, 76% developed
bone sarcomas and 16.0% developed soft tissue sarcomas
(Table 1). The mice succumbed to tumors by 14 months ofage and had a survival that is better than for the Trp53/
mice that we studied in our lineage-tracing analysis (Figure 2A).
This is expected, since these mice only rarely developed tumors
that were not sarcomas (Table 1) and as such succumbed to
sarcoma-related mortality.
We then generated Ng2/Cspg4-Cre;Trp53flox/+ and Ng2/
Cspg4-Cre;Trp53flox/ mice. The mice expressing only the
one conditional allele rarely developed tumors, while the
mice also expressing a null allele developed tumors at a fre-
quency equivalent to Ng2/Cspg4-Cre;Trp53flox/flox mice and
had a nearly identical survival curve (Figure 2B), providing
additional support to the concept that loss of Trp53 specif-
ically in an Ng2/Cspg4-expressing cell predisposes to sar-
coma formation.
The bone sarcomas displayed poorly marginated masses
with osteoid formation, an appearance characteristic of osteo-
sarcoma (Figures 2C and 2D). There was some heterogeneity
in the cytology, with two tumors displaying chondroblastic-
type osteosarcoma characteristics (Figure 2E). The osteosar-
comas arose from multiple bones (Figure 2F). 20% of mice
showed lung metastases (Figures 2G and 2H). Using X chromo-
some inactivation, as previously reported (Tsunashima et al.,
1996), we found the same pattern of inactivation in the bone
and lung lesions from female mice, suggesting that the lesions
derived from the same initial tumor (Figure S3).
Soft tissue sarcomas were also detected in mice (Figure 2I).
They arose from multiple tissues, including the cutaneous tis-
sues, retroperitoneum, muscle, and in one case arose from the
uterus. The soft tissue sarcomas were characterized by spin-
dle-shaped cells forming rough bundles and fascicles with hy-
perchromatic nuclei and abundant atypical mitoses (Figure 2J).
These sarcomas were consistent with undifferentiated pleomor-
phic sarcomas. Mice developing soft tissue sarcomas did not
show distant metastasis.
Localized Trp53 Deletion and Expression of KrasG12D in
Ng2/Cspg4-Expressing Cells Induces Soft Tissue
Sarcomas
We then investigated a mouse in which soft tissue sarcomas can
be generated using an inducible KrasG12D mutation and Trp53
deletion driven by Cre recombinase (Kirsch et al., 2007). TheseCell Reports 16, 917–927, July 26, 2016 919
Figure 2. Deletion of Trp53 in Ng2/Cspg4-Expressing Cells Causes Sarcomas, while Expression of a Stabilized Form of b-Catenin in Ng2/
Cspg4-Expressing Cells Causes Desmoid Tumors
(A) Kaplan-Meier survival curves inmonths of survival for mice expressing conditional Trp53 null alleles driven byNg2/Cspg4-Cre (red curve) andmice expressing
a germline deletion of Trp53 in both alleles (green curve). There is a significantly better survival inmice expressing Trp53 null alleles only inNg2/Cspg4-expressing
cells (P < 0.01).
(B) Kaplan-Meier survival curves in months of survival for Ng2/Cspg4-Cre;Trp53flox/flox (green curve) and Ng2/Cspg4-Cre;Trp53flox/- (red curve) showing little
difference in survival. )
(C–H) Osteosarcomas developed in the mice lacking Trp53 in Ng2/Cspg4-expressing cells. Radiographs (C), histology showing an osteoblastic (D) or a rare
chondroblastic phenotype (E), anatomic location of the osteosarcomas (F), and lung metastasis that developed (G and H).
(I and J) Soft tissue sarcomas developed in mice lacking Trp53 in Ng2/Cspg4-expressing cells. Gross (I) and histologic (J) view of a tumor, showing typical
histology for an undifferentiated pleomorphic sarcoma.
(K) Kaplan-Meier curves in weeks following localized 4-hydroxy-tamoxifen intramuscular injection in Ng2/Cspg4-CreER;Trp53flox/flox;KrasG12D mice for the
development of a palpable tumor.
(L) Typical histology of the soft tissue tumors that developed, an appearance consistent with undifferentiated pleomorphic sarcoma.
(M) Gross view of desmid tumors in the peritoneum of a mouse (arrows show tumors).
(N) Histology showing a typical appearance of a desmoid tumor that developed following tamoxifen regulated activation of the conditional stabilized b-catenin
allele.
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Figure 3. Comparative Expression between
Mouse and Human Tumors Showing Simi-
larities between Mouse and Human Osteo-
sarcomas
(A) Gene set enrichment analysis demonstrating
that genes differentially regulated in mouse
osteosarcoma are significantly enriched in human
osteosarcoma.
(B) Table showing gene set enrichment analysis
statistics for comparison of genes differentially
regulated in mouse osteosarcoma and various
subtypes of human sarcoma.mice develop localized sarcomas when injected with a virus
expressing Cre recombinase into muscle. To determine if Ng2/
Cspg4-expressing cells would drive soft tissue sarcomas in
LSL-KrasG12D;Trp53flox/flox mice, we crossed them with Ng2/
Cspg4-CreER mice, and drove expression of the conditional
alleles using localized tamoxifen injection into muscle. In this
way, recombination would occur in Ng2/Cspg4-expressing cells
at the injection site. 12 mice were studied, and they developed
a palpable soft tissue lesion 12 weeks following injection (Fig-
ure 2K), resulting in tumors with histology identical to that seen
in the soft tissue sarcomas generated by Trp53 deletion in the
same cell types (Figure 2L).
b-Catenin Stabilization in Ng2/Cspg4-Expressing Cells
Induces the Formation of Desmoid Tumors
To determine if stabilizing b-catenin mutations could induce
desmoid tumors, we crossed Ng2/Cspg4-CreER mice with
b-catenin conditionally stabilized Ctnnb1ex3 mice (Harada
et al., 1999). The conditional b-catenin Ctnnb1ex3 allele lacks
the phosphorylation sites in the amino terminal of b-catenin,
preventing its ubiquitin-mediated degradation, thus activating
b-catenin-mediated transcription. Mice were treated with
tamoxifen and developed desmoid tumors with an histology
identical to that seen in other murine desmoid tumors,
including infiltration into local muscle tissues (Figures 2M
and 2N).
Sarcomas from Ng2/Cspg4-CreER;Trp53flox/flox Mice
Show Expression of Genes Similar to Those Seen in
Human Tumors
A similar microarray platform as has been used in human tumors
was used to compare mRNA from sarcomas that developed
in Ng2/Cspg4-CreER;Trp53flox/flox mice with human tumors.
The mouse sarcoma data were deposited in the GEO database
(GEO: GSE63631). Gene expression data from a variety of hu-
man tumors were downloaded from the GEO (GEO: GSE2553).
Differential expression was compiled as a gene set that was
compared to expression data from various human cancer types
andwas called for each gene within each cancer type comparing
it to the aggregate of all other cancer types using a moderated
t-statistic. Gene set enrichment analysis (Mootha et al., 2003)Cwas carried out to identify the signifi-
cance of enrichment of the mouse genes
with the most differentially expressed hu-man genes that differentiate each cancer type. This showed the
strongest similarities between the same mouse and human sar-
coma subtypes (Figure 3). The expression pattern for the soft tis-
sue sarcomas was nearly identical to that previously reported
(Mito et al., 2009).
Mouse Sarcomas Express Genes that Are Distinct from
Trp53 Mutant Cells from which They Derive
Ng2/Cspg4-expressing cells were dissociated from non-
cancerous skeletal muscle and sorted using an Ng2/Cspg4
antibody. RNA was extracted and RNA sequencing performed
to determine gene expression differences between these cells
and sarcomas that developed in the same mice. The data
were deposited in the GEO database (GEO: GSE63679). Differ-
entially expressed genes were analyzed using gene set enrich-
ment analysis (Mootha et al., 2003), identifying the differential
regulation of multiple genes associated with decreased b-cate-
nin signaling in the tumors compared to the Ng2/Cspg4-
expressing cells (Figures 4A and 4B). Using RT-PCR, we veri-
fied differential expression of several b-catenin transcriptional
target genes (Figures 4C and 4D). While both activation and
inactivation of b-catenin transcription in sarcomas have been
reported (Dieudonne´ et al., 2010; Hoang et al., 2004; Iwao
et al., 1999; Iwaya et al., 2003; Lin et al., 2013; Matushansky
et al., 2007; Sakamoto et al., 2002; Wan et al., 2014),
our data showed that b-catenin-mediated transcription was
inactivated in both the bone and soft tissue sarcomas when
compared to Ng2/Cspg4-expressing cells.
Activation of b-Catenin Suppresses Sarcoma
Development and Growth
To determine the role of b-catenin stabilization in sarcoma for-
mation, we generated Ng2/Cspg4-Cre;Trp53flox/flox;;KrasG12D;
Ctnnb1ex3 mice in which Ng2/Cspg4-expressing cells would
harbor a mutation causing sarcomas and also express a stabi-
lized form of b-catenin. When the conditional alleles were acti-
vated using tamoxifen, mice did not develop tumors. Since
mice expressing the Ctnnb1ex3 allele would not form tumors,
we analyzed cells from sarcomas induced by a localized
injection of an adenovirus expressing Cre recombinase into
Trp53flox/flox;; KrasG12D mice. Sarcoma cells were dissociatedell Reports 16, 917–927, July 26, 2016 921
Figure 4. b-Catenin-Mediated Signaling Is
Downregulated in Sarcoma, and Its Activa-
tion Inhibits Tumor Growth
(A and B) Gene set enrichment analysis from RNA-
sequencing data comparing tumors to Ng2/
Cspg4-expressing cells lacking Trp53 showing
inhibition of b-catenin-mediated signaling in both
soft tissue sarcomas (A) and osteosarcomas (B).
(C and D) RT-PCR verifying downregulation of
expression of b-catenin transcriptional target
genes in murine tumors, soft tissue sarcomas (C),
and osteosarcomas (D). Data are given as relative
expression compared to Ng2/Cspg4-expressing
cells lacking Trp53, which is arbitrarily defined
as ‘‘1.’’
(E and F) Treatment of soft tissue sarcomas from
Trp53flox/flox;KrasG12D mice grafted into immuno-
deficient mice treated with lithium results in a
5-fold increase in b-catenin protein level (E) and
a significantly lower weight in grams (F) as
compared to controls.
(G) Soft tissue sarcomas from Trp53flox/flox;
KrasG12D mice expressing a stabilized version of
b-catenin grafted into immunodeficient mice had a
significantly lower weight in grams as compared to
controls.
(H–J) Treatment of human undifferentiated pleo-
morphic sarcomas and osteosarcomas estab-
lished as xenografts in immunodeficient mice with
lithium results in a more than 5-fold increase
b-catenin protein level in both tumor types (H)
and a lower weight in grams in treated soft tissue
sarcomas (I) and osteosarcomas (J). Means
and 95% confidence intervals are shown for all
data, with an asterisk indicating a decline with a
p < 0.05.and studied as grafts in immunodeficient NOD-scid IL2rgnull
mice (Wang et al., 2012). 10,000 cells were implanted subcuta-
neously, along with Matrigel. b-Catenin was activated by adding
lithium to the drinking water at a known effective dose (Chen
et al., 2007). As a second approach, the cell cultures were
infected with a lentivirus expressing the DN89-b-catenin922 Cell Reports 16, 917–927, July 26, 2016(a stabilized form of b-catenin that retains
its signaling functions) construct, or
an empty control, as previously reported
(Fuerer and Nusse, 2010; Li et al.,
1998). With lithium treatment (Figures 4E
and 4F) or with expression of the stabi-
lized form of b-catenin (Figure 4G),
we observed significantly smaller tumor
weights after 4 weeks.
Individual cells from ten primary human
osteosarcomas or undifferentiated pleo-
morphic sarcomaswere used to establish
xenografts in immunodeficient NOD-scid
IL2rgnull mice as previously reported
(Wang et al., 2012). Similar to the work
in murine tumors, mice were treated
with lithium (Chen et al., 2007). This re-sulted in a substantial increase in b-catenin protein levels in
the tumor tissues (Figure 4H) and a substantial decrease in tumor
volume (Figures 4I and 4J). These data are consistent with the
notion that b-catenin transcriptional activity is lower in sarcomas
than in the cells they arise from and that stabilization of b-catenin
in sarcomas can suppress tumor growth.
DISCUSSION
Identifying the cell of origin of tumors is critical to determine
the genetic events important in neoplastic progression and to
develop models of cancers in mice that more accurately reflect
human disease. However, for common sarcomas, the precise
cellular origin is unclear. Since sarcomas have mesenchymal
properties, mesenchymal stromal cells (MSCs) have been inves-
tigated as the cell of origin. Indeed, driving expression of onco-
genes in this cell type can give rise to sarcomas (Mohseny
et al., 2009; Rubio et al., 2013; Shimizu et al., 2010; Xiao et al.,
2013). However, MSCs are a heterogeneous population of cells.
Pericytes are mesenchymal cells that surround endothelial cells,
have a multi-differentiation mesenchymal potential, and express
genes that can be used as lineage markers in vivo (Covas et al.,
2008; Crisan et al., 2008; Dellavalle et al., 2007). Our studies
showed that both sarcomas and desmoid tumors can derive
from Ng2/Cspg4-expressing cells, most likely from pericytes.
By also using tamoxifen-inducible mice, our interpretation
of the cell of origin for these mesenchymal tumors is not
confounded by unanticipated expression of Cre during develop-
ment, which has been shown for some constitutive Cre lines,
such as Myf6-Cre.
Ng2/Cspg4 is expressed not only in pericytes but also in other
cell types. As such, our lineage-tracing studies with Ng2/Cspg4-
Cre mice cannot rule out the possibility that the mouse tumors
are derived from other Ng2/Cspg4-expressing cells. However,
our analysis of LacZ-labeled cells in the absence of tumors in
the limbs shows that Ng2/Cspg4-expressing cells express high
levels of the pericyte marker CD146. It is also possible that sar-
coma cells in this model might activate Ng2/Cspg4 expression
during early tumorigenesis and thereby lineage-tag the tumor
cells. While this possibility cannot be completely eliminated,
the generation of sarcomas in Ng2/Cspg4-CreERmice following
tamoxifen-inducible Cre suggests that the cell of origin of these
mesenchymal tumors expresses Ng2/Cspg4 at tumor initiation.
Mice with Trp53 mutations in Ng2/Cspg4 developed both oste-
ogenic and soft tissue sarcomas a finding consistent with the
notion that pericytes can differentiate into a variety of mesen-
chymal cell types. The concept that a mesenchymal progenitor
can form both bone and soft tissue sarcomas is in agreement
with data from driving oncogenic mutations in MSCs, showing
that the same mutation in MSCs can result in either bone or
soft tissue sarcomas (Rubio et al., 2010, 2013). Furthermore,
we found that different mutations in the same cell type can cause
differentmesenchymal tumors. Driving a stabilized form of b-cat-
enin in Ng2/Cspg4-expressing cells results in desmoid tumors,
while Trp53 deletion causes sarcomas. Therefore, the same
cell of origin can give rise to a variety of benign and malignant
tumor types, with the type of mutation determining the tumor
type that develops.
Tumors are intimately related to non-neoplastic stromal cells,
but since sarcomas have mesenchymal characteristics, the
identification of such cells in sarcomas has been problematic.
In our lineage-tracing studies, we found that sarcomas contain
a subpopulation of mesenchymal cells that do not stain for
LacZ. These cells likely represent a population of reactive
mesenchymal stromal cells within the sarcomas. The intermin-gling of reactive stromal cells within the neoplastic mesenchymal
cells raises complexity in the interpretation of pathologic data in
these tumor types, as it is difficult to distinguish these stromal
cells from the neoplastic cells. Indeed, some of the controversy
regarding roles in cell signaling activation and gene expression in
these tumor typesmay be related to detecting expression or bio-
logic findings from these normal cells. This is a notion supported
by the finding of normal mesenchymal progenitor cells in human
sarcomas (Morozov et al., 2010).
Other mouse osteosarcoma models have been developed
based on the conditional deletion or mutation of Trp53 (Berman
et al., 2008; Lin et al., 2009; Walkley et al., 2008). However,
driving deletion in a subset of cells and developing a sarcoma
does not necessarily identify a specific cell of origin. In our
work, a combination of lineage tracing and targeted deletion
supports the pericyte as a cell of origin. The anatomic distribu-
tion of tumors in our mouse model closely mimics the situation
in human sarcomas, the distal femur, proximal tibia, and prox-
imal humerus. In contrast, driving deletion of Trp53 in other
cell types, such as osteoblasts, results in 80% lesions in axial
skeletal sites (Berman et al., 2008; Lin et al., 2009; Walkley
et al., 2008).
Desmoid tumors are a clonal proliferation of mesenchymal
cells driven by mutations in APC or CTNNB1 driving b-catenin
protein stabilization (Alman et al., 1997a, 1997b; Tejpar et al.,
1999). Interestingly, while a subset of desmoid tumors were pre-
viously thought to be mutation negative when analyzed by tradi-
tional Sanger sequencing, deep sequencing (Aitken et al., 2015)
found that most of these mutation negative tumors do indeed
harbor mutations. Similar to the finding in sarcomas, not all
desmoid tumor cells in the mice stained for LacZ in the line-
age-tracing studies, and these non-staining cells may be non-
neoplastic stromal cells in the tumors. A high proportion of
normal cells in a tumor mass can mask the detection of a muta-
tion using traditional Sanger sequencing. Previous studies using
mice that develop desmoid tumors (Cheon et al., 2002; Smits
et al., 1998) to compare these tumors to normal cells are limited,
as themost appropriate normal cell control is unknown. Here, we
found a source of normal precursor cells for such analysis. The
finding that these tumors derive from pericytes is consistent
with data showing a correlation between numbers of mesen-
chymal progenitors and numbers of desmoid tumors that form
in Apc mutant mice (Wu et al., 2010).
The role of b-catenin in sarcomas has been controversial, with
both activation and inhibition reported. In addition, both activa-
tion and inhibition are suggested to increase tumor invasiveness
(Chen et al., 2007; Hoffman andBenoit, 2013; Li et al., 2008;Wan
et al., 2013). We found that b-catenin is inactivated in the sar-
comas compared to the Ng2/Cspg4-expressing cell from which
they derive. One possibility is that the undifferentiated pericytes
maintain a high b-catenin level and this must be downregulated
for differentiation into cells that become sarcomas. While our
data cannot rule out this possibility, the finding that stabilization
of b-catenin in these cells results in desmoid tumors, suggests
that high b-catenin alone does not maintain the pericytes in a
native undifferentiated state. Furthermore, driving b-catenin
stabilization in sarcomas also suppressed tumor growth. Thus,
similar to the situation in mesenchymal cell differentiation duringCell Reports 16, 917–927, July 26, 2016 923
development and repair, the level of b-catenin protein is impor-
tant in mesenchymal neoplasia, with higher or lower levels
contributing to pathology. In this situation, its activation causes
a benign locally invasive tumor, but its inhibition is required for
sarcoma formation. This is a notion similar to that in colon can-
cer, where b-catenin needs to be maintained at the right level
for cancer development (Albuquerque et al., 2002). The require-
ment for the precise regulation of b-catenin in mesenchymal
neoplasia raises the possibility that modulating its level could
be developed into a therapeutic approach for these tumor types.
EXPERIMENTAL PROCEDURES
Genetically Modified Mice
We used Trp53 mutant (Jacks et al., 1994), Apc1638N (Smits et al., 1998),
Trp53flox/flox conditional (Marino et al., 2000), LSL-KrasG12D, Catnbex3 (Harada
et al., 1999), Ng2/Cspg4-Cre and Ng2/Cspg4-CreER transgenic (Feng et al.,
2010; Zhu et al., 2008, 2011), and Rosa26RlacZ reporter (Soriano, 1999)
mice as previously reported. Ng2/Cspg4-CreER;Rosa26RlacZ mice, Ng2/
Cspg4-CrERe;Rosa26RlacZ;Trp53+/ mice, Ng2/Cspg4-CrERe;Rosa26RlacZ;
Trp53/ mice, and Ng2/Cspg4-CreER;Rosa26RlacZ;Apc1638N mice were
generated by crossing these mouse lines for lineage tracing studies. Ng2/
Cspg4-CreER;Trp53flox/flox, Ng2/Cspg-CreER;Trp53flox/, Ng2/Cspg4-CreER;
Trp53flox/+, Ng2/Cspg4-CreER;Catnbex3, Ng2/Cspg4-Cre;Trp53flox/flox, Ng2/
Cspg4-Cre;Trp53flox/, and Ng2/Cspg4-Cre;Trp53flox/+ mice were generated
by crossing the mice and used to determine if driving mutations in Ng2/
Cspg4-expressing cells causes tumors. In addition, Ng2/Cspg4-Cre;
Trp53flox/flox;Catnbex3 mice were generated. In the case of inducible Cre
strains, the transgene was activated by daily intraperitoneal injection of tamox-
ifen for 1 week after weaning. Trp53flox/flox;; LSL-KrasG12D mice (Kirsch et al.,
2007), were used in crosses with Ng2/Cspg4-CreERmice to generate soft tis-
sue sarcomas, but tamoxifen was injected locally into the muscle. All of the
comparisons from different genotypes were performed on littermates. An
equal number of male and female mice were used in each study. The endpoint
for the Kaplan-Meier survival curve was when amouse was found dead or was
sacrificed due to poor health. Mice that were sacrificed or found dead were
investigated using a systematic autopsy to identify the exact tumor type and
tumor location. Radiographs of the whole bodies of mice were obtained by us-
ing the Faxitron MX20 X-ray system (Faxitron Bioptics). All mouse protocols
were approved by the animal care committee of the Toronto Center for Pheno-
genomics or the Institutional Animal Care and Use Committee committee of
Duke University.
qPCR
Total RNA from mouse sarcomas and non-cancerous tissues was extracted
using TRIzol reagent (Invitrogen). RNA was used to generate single-strand
cDNA using SuperScript II reverse transcriptase (Invitrogen). To detect
mRNA level, real-time qPCR was performed. TaqMan primers were used
and the DDCt method was used for the analysis of the data.
Microarray
For microarray, total RNAs were extracted from osteosarcomas (n = 4) and soft
tissue sarcomas (n = 4) that developed in Ng2/Cspg4-Cre;Trp53flox/flox mice.
Skeletal muscle tissues (n = 2) and bone marrow tissues (n = 2) were used as
controls. Biotinylated cRNAwas hybridized ontoMouseWG-6 v2.0 Expression
BeadChips (Illumina). To identify gene signatures differentially expressed be-
tween sarcomas and non-cancerous tissues, linear models for microarray
data were used. The false discovery rate was set at 0.01, and evaluated using
Benjamini and Hochberg multiple testing procedures. Differential expression
was compiled as a gene set thatwas compared to expression data from various
humancancer types,withgeneexpressioncalled foreachgenewithineachcan-
cer type comparing it to the aggregate of all other cancer types using a moder-
ated t-statistic. Gene set enrichment analysis (Mootha et al., 2003) was carried
out to identify the significance of enrichment of the mouse genes with the most
differentially expressed human genes that differentiate each cancer type.924 Cell Reports 16, 917–927, July 26, 2016Cell Sorting
To isolateNg2/Cspg4-expressing cells, tissueswere harvested frommice, and
dissociated into individual cells as previously reported (Wang et al., 2012; Wu
et al., 2007). Flow cytometry was used to sortNg2/Cspg4-expressing cells us-
ing an NG2 Ab (Abcam). Sorting for LacZ (Amini-Nik et al., 2011) and CD146
(Wei et al., 2015) was performed as we previously reported.
RNA Sequencing
For each sample, 10 ng total RNA was processed using the SMARTTM cDNA
synthesis protocol including SMARTScribe Reverse Transcriptase. The ampli-
fied cDNA was subject to Illumina paired-end library construction. RNA-
sequencing analysis was performed by the Genome Sciences Centre at the
British Columbia Cancer Agency (Vancouver, Canada) using Illumina HiSeq
2000 sequencing at 75 base PET indexed lane, pooling two libraries per
lane. Data were processed using the TrimGalore toolkit (Chen et al., 2014) to
trim low-quality bases and Illumina sequencing adapters from the 30 end of
the reads. Only pairs where both reads were 35 nt or longer were kept for
further analysis. Reads were mapped to the GRCm38.73 version of the mouse
genome and transcriptome (Kersey et al., 2012) using the STAR RNA-
sequencing alignment tool (Dobin et al., 2013). Gene counts were compiled
using the HTSeq tool (http://www-huber.embl.de/users/anders/HTSeq).
Normalization and differential expression were carried out using the DESeq2
(Love et al., 2014) Bioconductor (Gentleman et al., 2004) package with the R
statistical programming environment (http://www.r-project.org). A negative
binomial generalized linear model was employed to identify differentially ex-
pressed genes across sample types. Pathway analyses were performed using
gene set enrichment analysis with parameters set to 2,000 gene set per muta-
tions and gene sets size between 8 and 500 (Subramanian et al., 2005). Gene
sets were obtained from the KEGG, MsigDB-c2, NCI, Biocarta, IOB, Netpath,
Human Cyc, Reactome, and Gene Ontology (GO) databases (Kanehisa and
Goto, 2000; Merico et al., 2010). An enrichment map was generated using Cy-
toscape with parameters set for a nominal p value of < 0.005, a false discovery
rate < 0.25, and the Jaccard coefficient set to 0.5 (Saito et al., 2012).
Xenograft in Immunocompromised Mice
Primary sarcomaswere dissociated into single cells (Wang et al., 2012). 10,000
dissociated cells were suspended with Matrigel (Becton Dickinson) and in-
jected subcutaneously into 6- to 8-week-oldNOD-scid IL2rgnull (NSG)mice. Af-
ter injection, themicewereobserved for 3weeks, and then lithiumwasadded to
the drinking water at a dose previously shown to increase b-catenin in mesen-
chymal tissues (Chen et al., 2007). The DN89-b-catenin construct, or empty
control, was used as previously reported (Fuerer and Nusse, 2010; Li et al.,
1998). Western analysis using an antibody to actin as a loading control (Tejpar
et al., 1999) was used to determine b-catenin levels, and the tumors were
weighed using an analytical balance, as previously reported (Wanget al., 2012).
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